Health Economics›Non-small cell lung cancer nonsquamous›Advanced or metastatic disease subsequent lines of therapy

Advanced or metastatic disease subsequent lines of therapy

Non-small cell lung cancer nonsquamous · 7 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 5 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Paclitaxel and Bevacizumab Variant #01	—	R 40 037	28d	5.4 mo	—	6	R 240 222 PFS proxy	1
Sorafenib monotherapy Variant #04	—	R 37 339	28d	—	8.2 mo	—	—	1
Gefitinib monotherapy Variant #01	—	R 8 556	28d	6.5 mo	—	8	R 68 444 PFS proxy	1
Nintedanib and Pemetrexed Variant #01	—	R 8 018	21d	4.4 mo	—	7	R 56 124 PFS proxy	1
Docetaxel monotherapy N/A - secondary systemic drug	—	R 243	28d	4.0 mo	10.6 mo	5	R 1 216 PFS proxy	3
Pemetrexed monotherapy N/A - secondary systemic drug	—	R 69	21d	3.6 mo	—	6	R 417 PFS proxy	1
Nivolumab monotherapy Variant #01 Partial	—	—	14d	—	12.2 mo	—	—	1

7 of 7 regimens shown